Moolec Science Sa · NASDAQ:MLEC
Moolec Science Sa — Q3 FY2023 Earnings Presentation
25 slides from Moolec Science Sa's earnings presentation, May 31, 2023
Slide 1: Business Update Conference Call 3rd Quarter Fiscal Year 2023
SCIENCE IN ALTERNATIVE PROTEINS Business Update Conference Call 3rd Quarter Fiscal Year 2023 May 31, 2023
Slide 2: Disclaimer
SCIENCE IN Disclaimer ALTERNATIVE PROTEINS This presentation was prepared for informational purposes only by Moolec Science SA, (“Moolec”). The information provided in this presentation is intended to highlight certain matters bearing upon the current status of Moolec that may be of interest to pote
Slide 3: Agenda
Agenda SCIENCE IN ALTERNATIVE PROTEINS 1 Scientific and operational milestones delivered 2 Integration of upstream & downstream capabilities 3 Business plan overview 4 Financial highlights .03 Conference Call 3rd Quarter Fiscal Year 2023
Slide 4: 1. Scientific and operational milestones delivered
SCIENCE IN ALTERNATIVE PROTEINS 1. Scientific and operational milestones delivered
Slide 5: Latest Milestones
Latest Milestones SCIENCE IN ALTERNATIVE PROTEINS PROGRAM HOST HIGHLIGHTS Cheese replacements • Molecular seeds multiplication is on schedule. USDA and Nutraceuticals Safflower • GLA oil expression levels were 60%, 10% above expectations. (United States Department of (Chymosin & GLA) • USDA-APHIS re
Slide 6: Pipeline Status
Pipeline Status SCIENCE IN ALTERNATIVE PROTEINS R&D OPERATIONS REGULATION PROGRAM HOST PROJECT DISCOVERY TRANSFORMATION DEVELOPMENT SELECTION SCALE-UP DOWNSTREAM STATUS Cheese replacements SPC2 and Nutraceuticals Safflower (Chymosin & GLA) GLASO COMPLETED YEEA1 Yeast YEEA2 Latest Progress YEEA3 Late
Slide 7: Molecular Farming - SOOY R&D Stages
Molecular Farming - SOOY R&D Stages SCIENCE IN ALTERNATIVE PROTEINS Discovery Transformation Developments Selection T0 T1 T2 T3 - T4 - T5 T6 550 256 140 3 1 Real DNA Vectors Transgenic Events Transgenic events Transgenic events Transgenic events Transgenic event of animal meat proteins of were inser
Slide 8: Regulatory Status Review Clearence
Regulatory Status Review Clearence SCIENCE IN ALTERNATIVE PROTEINS • According to USDA-APHIS, Moolec’s GLA safflower plants pose no greater plant pest risk than non-genetically engineered safflower plants according to regulation found at 7 CFR part 340. • Impacts on Moolec’s operations: o Increase e
Slide 9: Scale-up Progress
Scale-up Progress SCIENCE IN ALTERNATIVE PROTEINS SPC2 GLASO YEEA1 Chymosin Gamma Linolenic Acid Meat Replacement Prototype Molecular Seeds Molecular Seeds Media Designing and Multiplication Multiplication Process Validation (Hectares) (Hectares) (Liters) 300.0 27.4 6X yield increase 20.0 ~60% expre
Slide 10: 2. Integration of upstream & downstream capabilities
SCIENCE IN ALTERNATIVE PROTEINS 2. Integration of upstream & downstream capabilities
Slide 11: Acquistion of Plant-Based Food Ingredient Capabilities
Acquistion of Plant-Based Food Ingredient Capabilities SCIENCE IN ALTERNATIVE PROTEINS • Strategically located state-of-the-art operating soybean processing facility with 10,000 tons/year installed capacity. • Development of textured vegetable products that serve as food ingredients in meat replacem
Slide 12: Upstream Capabilities: Bioceres HB4® Soybean MOU
Upstream Capabilities: Bioceres HB4® Soybean MOU SCIENCE IN ALTERNATIVE PROTEINS Deal terms: • Bioceres will progressively provide up to 20,000 tons of HB4® soybeans (working capital). • Soybeans will be paid with preferred equity (conversion to common shares deferred up to 3 years). Rationale: • Ma
Slide 13: Traceable and Sustainable Platforms
Traceable and Sustainable Platforms 1 SCIENCE IN ALTERNATIVE PROTEINS ~100 Farmers Low Water Low Carbon Chemicals Big Data Footprint Footprint Reduction (Monitoring) + The combination of Molecular Farming technology with HB4® platform will enable us to promote and include the best available farming
Slide 14: 3. Business plan overview
SCIENCE IN ALTERNATIVE PROTEINS 3. Business plan overview
Slide 15: Market size opportunity (2025e)
Market size opportunity (2025e) SCIENCE IN ALTERNATIVE PROTEINS TAM SAM (USD Bn) (USD Bn) Gamma linolenic acid (GLA)3 1.5 Chymosin2 0.3 Alternative protein4 78.0 Processed meat1 827 Bn Nutritional 37 Bn Texturized vegetable 734.2 protein for food6 lipids3 13.0 13.7 Rennet2 0.8 Nom-meat ingredients5
Slide 16: Global End-to-End Ingredient Platform
Global End-to-End lngredient Platform SCIENCE IN ALTERNATIVE PROTEINS Demo Center Self-owned industrial capabilities Customers Food producers & distributors Growers Established network Cultivation Clients .16 Conference Call 3rd Quarter Fiscal Year 2023
Slide 17: Added value & Margins
Business Plan Execution SCIENCE IN ALTERNATIVE PROTEINS 4 Downstream Enhanced + Molecular Contracted SOOY Functional Plant Stage & Ingredient SOY + MEAT PROTEIN Seeds Growers Production & Animal Protein Ingredients MLEC SOOY 3 Added value & Margins functional Enhanced Modified Contracted Downstream
Slide 18: 4. Financial highlights
SCIENCE IN ALTERNATIVE PROTEINS 4. Financial highlights
Slide 19: Corporate Structure
Corporate Structure1 SCIENCE IN ALTERNATIVE PROTEINS Strategic partners remain as Moolec's main shareholders 2 100% since inception. 3 80.0% The Biotech 20.0% Company LLC 4 Bringing key experience, advisory, scientific know-how, and access BG Farming 5 Other 13.7% to facilities to strengthen 2.1% 5.0
Slide 20: Financial overview and milestones
Financial overview and milestones SCIENCE IN ALTERNATIVE PROTEINS BCA LightJump (SPAC) Nasdaq listing Cash & Cash Acquisition of Downstream Debt issuance Bioceres Deal MOU $138M in trust Proceeds of $10M Equivalents of $6.2M Upfront payment of $2M $2M at 0% interest 20k tons of HB4® soybean 3Q FY 20
Slide 21: Preferred Equity MOU
Preferred Equity MOU 1 SCIENCE IN ALTERNATIVE PROTEINS At Closing: Commitment to payback in shares or cash up to USD 14 MM Terms: Maturity: 3 years. Commitment to deliver up to 20k tons Amount: Up to USD 14 MM. of HB4® soybean in the next 3 years Subscription: In kind, up to 20k tons of HB4® soybean
Slide 22: Annex: Condensed Consolidated Statements of Operations
Annex: Condensed Consolidated SCIENCE IN ALTERNATIVE PROTEINS Statements of Operations For the For the Change nine months nine months % ended ended March 31, March 31, 2023 2022 Continuing operations Research and development expense (980,585) (708,211) 38.5% Marketing expense (54,155) (61,353) (11.7
Slide 23: Annex: Condensed Consolidated Statements of Financial Position
Annex: Condensed Consolidated SCIENCE IN Statements of Financial Position ALTERNATIVE PROTEINS As of As of Change March 31, June 30, % 2023 2022 Non current assets 12,825,325 4,607,848 178.3% Current assets 7,159,108 1,083,869 560.5% Total assets 19,984,433 5,691,717 251.1% Equity 11,588,532 1,604,3
Slide 24: Annex: Condensed Consolidated Statements of Cash Flows
Annex: Condensed Consolidated SCIENCE IN ALTERNATIVE PROTEINS Statements of Cash Flows For the For the Change nine months nine months % ended ended March 31, March 31, 2023 2022 Net cash used in operating activities (4,845,837) (1,277,070) 279.4% Net cash used in investing activities (148,748) - n/a
Slide 25: Let's empower science in food for the good of the planet
SCIENCE IN ALTERNATIVE PROTEINS Let’s empower science in food for the good of the planet Follow us! moolecscience.com | ir.moolecscience.com